Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care

 ClinicalTrials.gov Identifier: NCT04598594

Sponsor:

Assistance Publique - Hôpitaux de Paris

See Contacts and Locations

Brief Summary:

There is currently no known treatment for COVID19. Active smokers are infrequent among patients with COVID-19 which has led our team to hypothesize that nicotine is responsible for this protective effect via the nicotinic acetylcholine receptor (nAChR). In fact, nAChR possess the ability to modulate ACE2 expression, the cellular doorway for SARS-CoV2. nAChR modulation by the virus would be responsible for the numerous clinical signs observed in COVID-19, including the cytokine storm manifested in intensive care hyperinflammatory patients.

Based on epidemiological data and experimental data from scientific literature, our team hypothesize that nicotine could inhibit the penetration and propagation of SARS-CoV2. Our team also claim that nicotine could attenuate the hyperinflammatory response and cytokine storm leading to acute respiratory failure and a probable multi-organ failure associated with COVID19.

Condition or disease	Intervention/treatment	Phase
Covid19SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere	Drug: Patch, NicotineDrug: Patch, Placebo	Phase 3

Estimated Study Start Date  :	November 2020
Estimated Primary Completion Date  :	September 2021
Estimated Study Completion Date  :	November 2021 https://clinicaltrials.gov/ct2/show/NCT04598594